Deutsche Bank AG Has $56.75 Million Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Deutsche Bank AG increased its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 1.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,778,377 shares of the company’s stock after purchasing an additional 30,867 shares during the quarter. Deutsche Bank AG’s holdings in Apellis Pharmaceuticals were worth $56,748,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. EverSource Wealth Advisors LLC grew its stake in shares of Apellis Pharmaceuticals by 2,707.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock valued at $25,000 after buying an additional 758 shares in the last quarter. Signaturefd LLC lifted its stake in Apellis Pharmaceuticals by 357.2% in the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock valued at $37,000 after acquiring an additional 918 shares during the last quarter. US Bancorp DE grew its position in shares of Apellis Pharmaceuticals by 70.0% in the 4th quarter. US Bancorp DE now owns 3,223 shares of the company’s stock valued at $103,000 after acquiring an additional 1,327 shares during the period. Covestor Ltd grew its position in shares of Apellis Pharmaceuticals by 1,819.2% in the 4th quarter. Covestor Ltd now owns 3,992 shares of the company’s stock valued at $127,000 after acquiring an additional 3,784 shares during the period. Finally, Russell Investments Group Ltd. increased its stake in shares of Apellis Pharmaceuticals by 89.0% during the 4th quarter. Russell Investments Group Ltd. now owns 6,107 shares of the company’s stock worth $195,000 after purchasing an additional 2,876 shares during the last quarter. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ APLS opened at $17.52 on Tuesday. The business has a fifty day moving average price of $21.15 and a two-hundred day moving average price of $27.05. The stock has a market capitalization of $2.20 billion, a PE ratio of -8.63 and a beta of 0.73. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $16.65 and a fifty-two week high of $43.99.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.38). The firm had revenue of $149.90 million for the quarter, compared to the consensus estimate of $197.61 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company’s revenue for the quarter was down 3.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.54) EPS. As a group, equities analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,569 shares of the company’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total transaction of $139,781.90. Following the completion of the sale, the general counsel now directly owns 138,730 shares in the company, valued at $3,482,123. This represents a 3.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on APLS shares. The Goldman Sachs Group reduced their price target on Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Robert W. Baird decreased their target price on Apellis Pharmaceuticals from $55.00 to $47.00 and set an “outperform” rating on the stock in a report on Thursday, May 8th. Royal Bank of Canada dropped their price target on Apellis Pharmaceuticals from $21.00 to $18.00 and set a “sector perform” rating on the stock in a research note on Thursday, May 8th. Scotiabank reduced their price objective on shares of Apellis Pharmaceuticals from $28.00 to $20.00 and set a “sector perform” rating for the company in a research report on Thursday, May 8th. Finally, Wedbush dropped their price objective on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd. Nine equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Apellis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.37.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).